Targeted Therapies for Solid Tumors : A Handbook for Moving Toward New Frontiers in Cancer Treatment.

Intro -- Contents -- Contributors -- Chapter-1 -- Introduction -- Chapter-2 -- Oncogene Addiction in Solid Tumors -- The Molecular Basis of Oncogene Addiction -- Future Perspectives -- References -- Chapter-3 -- Pharmacology and Clinical Development of New Molecularly Targeted Agents -- Introduction -- Definition of Molecularly Targeted Antitumor Agents -- Beyond Clinicopathological Typing: New Pharmacological Targets for Individualized Treatments -- Main Targets and Pharmacodynamics of Molecularly Targeted Antitumor Agents -- Agents Targeting Growth Factor Receptors -- Agents Targeting Key Downstream Signaling Pathways -- Agents Inhibiting Angiogenesis -- Pharmacokinetics -- Bioavailability -- Metabolism and Clearance -- Pharmacogenetics -- Conclusions -- References -- Chapter-4 -- Biomarkers as Prognostic, Predictive, and Surrogate Endpoints -- What Is a Biomarker? -- Potential Clinical Applications of Cancer Biomarkers -- Prognostic Biomarkers -- Predictive Biomarkers -- Surrogate Endpoints Biomarkers -- Circulating Biomarkers: The Concept of "Liquid Biopsy" -- Circulating Tumor Cells -- Circulating Tumor DNA -- New Perspectives and Future Applications -- References -- Chapter-5 -- Evaluation of Response in Malignant Tumors Treated with Targeted Agents -- RECIST 1.1 -- What to Measure? -- Special Considerations Regarding Lesion Measurability: -- How to Assess Disease Progression? -- Response Criteria -- When to Asses Disease? -- Imaging Considerations -- Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) -- Limits of RECIST 1.1 in Target Therapies and Modern Criteria -- Imaging Modalities -- Tumor Response Criteria in Targeted Cancer Therapies -- GIST -- Hepatocellular Carcinoma -- mRECIST and HCC -- EASL Criteria and HCC -- Malignant Melanoma -- High-Grade Malignant Glioma -- PERCIST -- References -- Chapter-6.

Targeted Therapies for HER2-positive Breast Cancer -- Introduction -- Approved Anti-HER2 Agents -- Trastuzumab -- Metastatic Setting -- Early Setting -- Trastuzumab-related Cardiotoxicity -- Lapatinib -- Mechanisms of Resistance -- Pertuzumab -- Trastuzumab-emtansine (T-DM1) -- Novel Anti-HER2 Drugs -- Neratinib -- Targeted Agents Combinations Including an Anti-HER2 Drug -- Dual Anti-HER2 Blockade -- Anti-HER2 Agents Plus Endocrine Therapies -- Other Combinations -- Anti-HER2 Blockade Beyond Progression -- Conclusions -- References -- Chapter-7 -- Role of Poly ADP-Ribose Polymerase (PARP) Inhibitors in Triple-Negative Breast Cancer (TNBC) -- Poly ADP-ribose Polymerase Inhibitors, DNA Damage Repair Dysfunction, and the Synthetic Lethality -- DDR Dysfunction and Clinically Relevant Biomarkers -- DDR Dysfunction and Synthetic Lethality Through PARP Inhibition -- Clinical Trials with PARP Inhibitors -- Triple-Negative Breast Cancer (TNBC) and DDR Dysfunction -- Clinical Trials with PARP Inhibitors in BC and TNBC -- References -- Chapter-8 -- Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck -- EGFR-Directed Monoclonal Antibodies -- Platinum-Refractory Disease -- First Line R/M SCCHN -- Locoregionally Advanced Disease -- EGFR Tyrosine Kinase Inhibitors -- Conclusion -- References -- Chapter-9 -- Targeted Therapies for Non-Small Cell Lung Cancer -- Introduction -- EGFR-Tirosine-Kinase Inhibitors -- EGFR mutations -- EGFR-Tirosine-Kinase Inhibitors (TKIs) -- EGFR-TKIs' Toxicity -- ALK-Inhibitors -- EML4-ALK Chromosome Rearrangement -- EML-ALK Inhibitors: Crizotinib -- ALK inhibitors Toxicitiy -- Overcoming Acquired Resistance: New Target Therapies -- Mechanisms of EGFR-TKIs Resistance -- New EGFR Inhibitors -- Mechanisms of Crizotinib Resistance -- New ALK Inhibitors -- Conclusions -- References -- Chapter-10.

Targeted Therapies for Gastric Cancer -- Introduction -- Molecular Targets in Gastric Cancer -- Cell Surface Receptor Inhibitors -- Human Epidermal Growth Factor Type 2 (HER2) Inhibition -- Epidermal Growth Factor Receptor (EGFR) Inhibition -- Vascular Endothelial Growth Factors Inhibition (Anti-Angiogenesis) -- Insulin-like Growth Factor-1 (IGF-1) Inhibition -- Fibroblast Growth Factor Tyrosine Kinase Inhibitors -- c-Met Tyrosine Kinase Inhibitors -- Cell Cycle Inhibition -- Polo-like Kinase Inhibitors -- Aurora Kinase Inhibitors -- Cyclin-Dependent Kinase Inhibitors -- Other Novel Targets -- Ubiquitin-Proteasome Pathway Inhibitors -- PI3 Kinase Pathway Inhibition -- Heat Shock Protein 90 Inhibitors -- Matrix Metalloproteinases (MMPs) -- Histone Deacetylase Inhibitors -- Protein Kinase C Inhibition -- Poly ADP-ribose Polymerase Inhibitors -- Conclusion -- References -- Chapter-11 -- Targeted Therapies for Pancreatic Cancer -- Introduction -- Tumor Stroma -- Pancreatic Cancer Stem Cells -- Oncofetal Signaling Pathways: Notch and Hedehog -- γ-secretase inhibitors (GSI) -- Sulforaphane -- Diferuloylmethane -- Survival Pathways -- EGFR -- PI3K/AKT/mTOR -- IGF1-R -- Approaches Targeting Angiogenesis -- Inmunotherapy -- Conclusions -- References -- Chapter-12 -- Targeted Therapies in Hepatocellular Carcinoma -- Introduction -- Target Therapy Related to Biological Pathways -- Monotherapy -- MAP-Kinase-Mediated Pathway -- PI3K/Akt/mTOR-Mediated Pathway -- Wnt/β-catenin-Mediated Pathway -- Hedgehog-Mediated Pathway -- Combination Therapy -- Conclusions -- References -- Chapter-13 -- Targeted Therapies for Colorectal Cancer -- Salvage Targeted Therapy in mCRC -- Systemic Therapies for Patients with Initially Resectable Liver Metastases -- Pre- and Perioperative Chemotherapy -- Postoperative or Adjuvant Chemotherapy -- Combining Anti-VEGF and Anti-EGFR.

The Development of New Targeted Agents -- Targeted Therapies in Adjuvant Treatment -- Conclusions -- References -- Chapter-14 -- Targeted Therapy in Gastrointestinal Stromal Tumors -- Introduction -- Oncogenic Mutations in GISTs -- Markers of Progression in the GIST Management -- Introduction of Imatinib Mesylate in the Therapy of GISTs -- Imatinib Mesylate in the Targeted First-line Therapy of Advanced GISTs -- Adjuvant Therapy with Imatinib -- Neoadjuvant Therapy with Imatinib -- Imatinib Resistant GISTs -- Treatment Options for Imatinib Resistant GISTs -- Experimental Therapy of Imatinib- and Sunitinib-resistant GISTs -- Alternative Kinase Inhibitors -- Alternative Targets and Their Antagonists -- References -- Chapter-15 -- Targeted Therapies in Kidney Cancer -- Introduction -- Molecular Biology of Kidney Cancer -- Clear Cell Renal Cell Carcinoma -- Papillary Type I Renal Cell Carcinoma -- Papillary Type II RCC -- Chromophobe Renal Cell Carcinoma -- Clinical Development of VEGF-Targeted Therapy in RCC -- Targeting the Ligand: Anti-VEGF Antibody -- Bevacizumab -- Targeting the Receptor: Small-­Molecules Blocking VEGFR Activity -- Sorafenib (BAY 43-9006) -- Sunitinib (SU11248) -- Pazopanib (GW786034) -- Axitinib (AG013736) -- Tivozanib (AV-951) -- Mechanistic Target of Rapamycin (mTOR) Inhibitors -- Temsirolimus (CCI-779) -- Everolimus (RAD001) -- New Generation PI3K-AKT-mTOR Agents -- Double PI3K-mTOR Inhibition: NVPBEZ235 -- AKT Inhibition: Perifosine -- Upcoming Agents in Renal Cell Cancer -- Last Generation Anti-Angiogenics -- Cediranib -- Dovitinib -- AMG-386 (Trebananib) -- Aflibercept -- Regorafenib -- MET Inhibitors -- Foretinib -- AMG 102 -- ARQ 197 (Tivantinib) -- Cabozantinib -- Conclusions -- References -- Chapter-16 -- Targeted Therapies in Melanoma -- Introduction -- Molecular Biology of Melanoma -- Genetic Risk Factors.

The RAS/RAF/MEK/ERK Signaling Pathway -- Current and Emerging Approaches in Melanoma Treatment -- Chemotherapy -- New Targeted Therapies in Melanoma -- BRAF Inhibitors -- MEK Inhibitors -- c-KIT Inhibitors -- Immunotherapy -- Immunotherapy Targeting CTLA-4 -- Immunotherapy Targeting PD-1 and PD-L1 -- Conclusions -- References -- Chapter-17 -- Targeted Therapies for Prostate Cancer -- Introduction -- Targeting Androgen Receptor (AR)-Associated Signaling in the Treatment of Prostate Cancer -- Targeting Non-AR-Mediated Signaling -- Endothelins -- Antiangiogenic agents -- Bevacizumab -- Aflibercept -- Tasquinimod -- Lenalinomide -- Tirosin Kinases -- Sorafenib -- Sunitinib -- Chaperone Proteins -- Phosphoinositide-3-Kinase-Akt-Mammalian Target of Rapamycin Pathway -- IGF-1R Pathway -- Poly (ADP-ribose) polymerase -- MET -- Src -- Immunotherapy -- Antibodies -- Ipilimumab (Anti-CTLA4, MDX-010) -- Prostate Specific Membrane Antigens and Antibodies (J591) -- Vaccines -- Sipuleucel-T (APC8015, Provenge) -- GVAX -- PROSTVAC-VF Vaccine (PSA-TRICOM) -- TG4010 -- Bone-targeted therapy -- Bisphosphonates -- Denosumab -- Radiopharmaceuticals -- Conclusions -- References -- Chapter-18 -- Targeted Therapies for Bone Metastases -- Introduction -- Targeted Therapies for Bone Metastatic Solid Cancers -- Tumor-Targeted Therapies: The Example of Advanced Prostate Cancer -- Hormonotherapy in Bone Metastatic Prostate Cancer -- Biologic Therapy in Bone Metastatic Prostate Cancer -- Bone-Targeted Therapies -- Bisphosphonates -- Denosumab -- Bone Anabolic and Anticatabolic Agents -- Systemic Radionuclide Therapies -- Myeloma Bone Disease (MBD): Approaches of Target Therapy -- Conclusion -- References -- Index.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.